Otonomy (NASDAQ:OTIC) Stock Passes Below 200-Day Moving Average of $0.32
Otonomy (NASDAQ:OTIC) Stock Passes Below 200-Day Moving Average of $0.32
Otonomy, Inc. (NASDAQ:OTIC – Get Rating)'s share price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.32 and traded as low as $0.11. Otonomy shares last traded at $0.11, with a volume of 1,426,584 shares.
Otonomy 公司（NASDAQ：ODDAQ-獲取評級）的股價在周三交易期間超過 200 天移動平均線以下。該股票的 200 天移動平均線為 0.32 美元，交易價格低至 0.11 美元。奧托米股票最後交易價為 0.11 美元，成交量為 1,426,584 股。
Analyst Upgrades and Downgrades
分析師升級和降級
OTIC has been the topic of a number of research reports. Piper Sandler cut Otonomy from an "overweight" rating to a "neutral" rating and lowered their price objective for the company from $3.00 to $0.50 in a research report on Thursday, October 13th. StockNews.com started coverage on Otonomy in a research report on Thursday. They issued a "hold" rating for the company.
奧迪一直是多項研究報告的主題。派珀·桑德勒（Piper Sandler）在 10 月 13 日（星期四）的一份研究報告中，將 Otonomy 從「超重」評級降至「中性」評級，並將公司的價格目標從 3.00 美元降至 0.50 美元。StockNews.com 在周四的一份研究報告中開始對 Otonomy 進行報導。他們為公司頒發了「持有」評級。
Otonomy Price Performance
Otonomy 的價格表現
The company's 50-day moving average is $0.11 and its two-hundred day moving average is $0.32. The company has a market cap of $7.10 million, a P/E ratio of -0.14 and a beta of 1.55.
該公司的 50 天移動平均線為 0.11 美元，其 200 日移動平均線為 0.32 美元。該公司的市值為 710 萬美元，市盈率為 -0.14，測試版為 1.55。
Hedge Funds Weigh In On Otonomy
對沖基金對 Otonomy 的權衡
A number of hedge funds have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. bought a new position in Otonomy in the third quarter valued at approximately $1,621,000. Lynx1 Capital Management LP boosted its holdings in Otonomy by 7,609.6% in the third quarter. Lynx1 Capital Management LP now owns 2,312,880 shares of the biopharmaceutical company's stock worth $682,000 after acquiring an additional 2,282,880 shares in the last quarter. Requisite Capital Management LLC purchased a new stake in shares of Otonomy during the third quarter valued at approximately $44,000. Dimensional Fund Advisors LP boosted its holdings in shares of Otonomy by 17.7% in the first quarter. Dimensional Fund Advisors LP now owns 841,694 shares of the biopharmaceutical company's stock worth $2,020,000 after acquiring an additional 126,747 shares during the period. Finally, Two Sigma Investments LP lifted its stake in Otonomy by 129.2% during the third quarter. Two Sigma Investments LP now owns 142,183 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 80,153 shares during the last quarter. Institutional investors and hedge funds own 41.23% of the company's stock.
一些對沖基金最近增加或減少了他們在業務中的賭注。72 點資產管理有限責任公司在第三季度買入了一個新的頭寸，價值約為 1,621,000 美元。Lynx1 資本管理有限公司在第三季度將其在 Otonomy 的持有量提高了 7,609.6％。林 1 資本管理有限公司在上一季度額外收購 2,282,880 股股份後，擁有該生物製藥公司股票的 2,312,880 股，價值 682,000 美元。必要資本管理有限責任公司在第三季度購買了 Otonomy 股份的新股份，價值約為 44,000 美元。維基金顧問 LP 在第一季度將其在 Otonomy 股份的持有量提高 17.7%。維基金顧問 LP 現在擁有該生物製藥公司的 841,694 股股票，價值 2,020,000 美元，在此期間額外收購 126,747 股股票。最後, 兩西格瑪投資 LP 在第三季度解除了其在 Otonomy 的股份 129.2%.兩個西格瑪投資 LP 現在擁有 142,183 股的生物製藥公司的股票價值 $42,000 在上一個季度購買了額外的 80,153 股後。機構投資者和對沖基金擁有公司股票的 41.23%。
Otonomy Company Profile
音之美公司簡介
(Get Rating)
(取得評分)
Otonomy, Inc operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss.
Otonomy, Inc 是一家生物製藥公司。從事神經病學治療藥物的開發。該公司的產品線包括奧替維克斯（地塞米松）梅尼爾氏病，奧替普利（環丙沙星懸浮液）急性中耳炎，帶管（AOMT），OTO-313（加基克列定）耳鳴，OTO-413（BDNF）隱性聽力損失，OTO-510（耳保護劑）防止耳朵重度損失（CIPHL），致聽力損失（CIHL）嚴重聽力損失（CIHL）。OTO-6XX
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Otonomy (OTIC)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
- 免費獲取有關 OTONNOMY 的研究報告
- 竹篙股票值得嗎？您應該投資竹篙股嗎？
- 齊默生物特在盈利上擊敗，增長可能會定價
- 人工智能軟件製造商 EPAM 擁有最大的技術行業集會
- 大盈利翻牌後福特股票前進
- 業內人士和機構購買金剛狼全球
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Otonomy 日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收 Otonomy 和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。